Search results
Results from the WOW.Com Content Network
Esketamine, sold under the brand names Spravato (for depression) and Ketanest (for anesthesia) among others, [10] [12] is the S(+) enantiomer of ketamine. [ 5 ] [ 13 ] It is a dissociative hallucinogen drug used as a general anesthetic and as an antidepressant for treatment of depression .
Spravato is made from esketamine, which is derived from ketamine—a Schedule III drug that’s FDA-approved as an anesthetic (and often abused) but has shown promise as an off-label IV treatment ...
An enantiomer of ketamine – esketamine commercially sold as Spravato – was approved as an antidepressant by the European Medicines Agency in 2019. [63] Esketamine was approved as a nasal spray for treatment-resistant depression in the United States [64] and elsewhere in 2019 (see Esketamine and Depression). The Canadian Network for Mood and ...
Esketamine, sold under the brand name Spravato and produced by Janssen Pharmaceuticals, was approved by the FDA in March 2019 for the treatment of Treatment-Resistant Depression (TRD) and suicidal ideation. [8] As of 2022, it is the only psychoplastogen approved in the US for the treatment of a neuropsychiatric disorder. [6]
Risk Evaluation and Mitigation Strategies (REMS) is a program of the US Food and Drug Administration for the monitoring of medications with a high potential for serious adverse effects. REMS applies only to specific prescription drugs, but can apply to brand name or generic drugs. [1] The REMS program was formalized in 2007.
Esketamine (Spravato) – non-competitive NMDA receptor antagonist, other actions [13] Gepirone (Exxua) – 5-HT 1A receptor partial agonist and α 2-adrenergic receptor antagonist; Opipramol (Insidon) — σ 1 receptor agonist, other actions; Tianeptine (Stablon, Coaxil, Tianeurax) – weak and atypical μ-opioid receptor agonist, other actions
This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved.
A systematic review of data comparing low-intensity CBT (such as guided self-help by means of written materials and limited professional support, and website-based interventions) with usual care found that patients who initially had more severe depression benefited from low-intensity interventions at least as much as less-depressed patients.